On March 23, 2021, we entered into a Manufacturing and Supply Agreement with FCDI, or, as amended, the Manufacturing Agreement, pursuant to which FCDI will provide certain agreed upon technology tran…
Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purpos…
Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC g…
Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…
Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: the sublicenses under the FCDI Agreem…
the sublicenses under the FCDI Agreements pursuant to our former Research Collaboration and License Agreement with Bristol-Myers Squibb dated January 7, 2022, or the Collaboration Agreement
Pursuant to the Letter Agreement, and in consideration for amending the FCDI Agreements, we paid to FCDI (i) an upfront payment of $10.0 million, and will pay (ii) a percentage of any milestone payme…
Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE g…
Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC g…
Reciprocal relationship from INAB graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from INAB graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from INAB g…
Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectivel…
Century Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IPSC-DEBT
Debt stack $43.6M
90%
Market cache reports total debt of $43.6M.
IPSC-DEBT-10343
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
IPSC-DEBT-10342
Warrants outstanding: 16112
90%
xbrl warrant detail from xbrl 2021-12-31.
Century Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Century Therapeutics, Inc..
Century Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
IPSC-OWNER-RA-CAPITAL-MANAGEMENT-L-P
RA CAPITAL MANAGEMENT, L.P.
90%
13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 75 tracked holders.
Century Therapeutics, Inc. Extended Supply Chain Network